William Blattner, M.D. Professor; Associate Director, Institute of Human Virology; Director of the Epidemiology and Prevention Division
Department:
Medicine
UMGCC Research Program:
Experimental Therapeutics Program Viral Oncology
Education/Training:
Medical Degree:
Washington University School of Medicine
Residency:
New York Cornell Medical Center and Memorial Sloan Kettering Cancer Institute
Contact
Information:
Mailing Address:
University of Maryland School of Medicine
The Institute of Human Virology
725 West Lombard Street
Baltimore, Maryland 21201
Email:
wblattner@ihv.umaryland.edu
Phone:
(410) 706-1941
Fax:
(410) 706-1944
Research Interests:
Dr. Blattners work focuses on accelerating the testing of HIV vaccine candidates and developing cohorts suitable for efficacy trials. His pathogenesis research focus continues in studies of acute infection and in estimates of HIV incidence in target populations. Focusing on Nigeria in collaboration with the Centers for Disease Control, he is playing a key role in developing capacity for implementing the Presidents Emergency Plan for AIDS Relief by supporting laboratory capacity building, training of providers and developing implementation structures to insure that antiviral therapy is delivered optimally to avoid the development of drug resistance.
As Chairman of the Baltimore AIDS Commission, Dr. Blattner is working in Baltimore to raise public awareness of the scope of the epidemic and the importance of preventative vaccines. He oversees an international training program funded by the Fogarty Center of the National Institutes of Health to train scientists and clinicians from the Caribbean, Nigeria and Mali.
Publications:
Goedert JJ, Charurat M, Blattner WA, Hershow RC, Pitt J, Diaz C, Mofenson LM, Green K, Minkoff H, Paul ME, Thomas DL, Whitby D. Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. AIDS, 17(3):425-33, 2003.
Tuomala RE, O'Driscoll PT, Bremer JW, Jennings C, Xu C, Read JS, Matzen E, Landay A, Zorrilla C, Blattner W, Charurat M, Anderson DJ. Cell-associated genital tract virus and vertica transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis, 187(3):375-84, 2003.
Constantine NT, Sill AM, Jack N, Kreisel K, Edwards J, Cafarella T, Smith H, Bartholomew C, Cleghorn FR, Blattner WA. Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less- sensitive test strategy. J Acquir Immune Defic Syndr. 32(1):94-103, 2003.
Poirier MC, Divi RL, Al Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr;33:175-83, 2003.
Blattner, W.A; Oursler,K.A.; Cleghorn F.R.; Charurat,M.; Sill,A.M.; Bartholomew,C.; Jack,N.; O'Brien T.R.; Edwards,J.; Tomaras,G.D.; Weinhold,K.; Greenberg,M. Rapid Viral Clearance Following Acute HIV-1 Infection: Correlates of AIDS Risk. J. Inf. Dis. 189 (10), 2004
Winchester R, Pitt J, Charurat M, Magder LS, Gahring HH, Landay A, Read JS, Shearer W, Handelsman E, Luzuriaga K, Hillyer GV, Blattner W. Mother-to-Child Transmission of HIV-1: Strong Association With Certain Maternal HLA-B Alleles Independent of Viral Load Implicates Innate Immune Mechanisms. J Acquir Immune Defic Syndr. 36(2):659-670, 2004.
Charurat M., Blattner WA, Hershow R., Buck A., Zorrilla C., Watts DH., Paul M., Landesman S, Adeniyi- Jones S, Tuomala R., for the Women and Infants Transmission Study. Changing Trends in Clinical AIDS Presentations and Survival among HIV-1-Infected Women. Journal of Women's Health 2004; 13:6, 711- 722.
Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, Larussa P, Landesman S, Rich KC. Risk Factors for In Utero and Intrapartum Transmission of HIV. J Acquir Immune Defic Syndr. 38 (1) 87-95, 2005.
Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu Y-L, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L, and the NIAID HIV Vaccine Trials Network. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 2005 Oct 1;192(7):1249-59. Epub 2005 Aug 31.
